Parameter
| Biomarker | KRASmut/p53mut (combined detection) | Full name | KRAS mutant + TP53 mutant | Molecular Type | Nucleic acid combination (DNA) |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Early diagnosis | ||
| Disease | Pancreatic Cancer | Disease Subtypes | / | ||
| Organ | Pancreas | Test Sample / Technology Platform | Plasma (single-cell exosome analysis, ctDNA sequencing) | ||
| Pathobiological Mechanisms | KRAS and p53 mutation is the most common PDAC, joint detection can cover the key drivers of the tumor | ||||
| Clinical Availability Status | Clinical research phase: in patients with stage I PDAC detection rate is high, the molecular evidence for early diagnosis | ||||
| Notes and Dynamics | Through the analysis of the single cell secrete outside body can be detected in patients with early, overcome the ctDNA limitations in the early days of low concentration | ||||